Kenvue Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
7.4%projected annual EPS growth
Analyst Coverage
12analysts covering
FY Revenue (est.)
$15.6Bnext fiscal year
FY EPS (est.)
$1.18next fiscal year
Monitoring Framework
Key Performance Indicators
Organic Sales Growth Quarterly1.2%Target: 2 to 4%
Absolute Greenhouse Gas Emissions Reduction (Direct Operations vs 2020 Baseline) Annually41.0%Target: 42 by 2030%
Global Electricity from Renewable Sources Annually0.8Target: 1.00 by 2030
Recyclable or Refillable Plastic Packaging Annually0.7Target: 1.00 by 2025
Watch Items
- Kimberly-Clark Merger Integration and Synergy RealizationTrigger: Pending regulatory approvals and closing conditions for the $48.7 billion transactionAction: Monitor progress toward the targeted $2.1 billion in run-rate synergies and operational integration timelines.
- Tylenol (Acetaminophen) Litigation and Public PerceptionTrigger: Trump administration reports or legal actions linking acetaminophen use during pregnancy to autismAction: Assess impact on Tylenol sales, which account for an estimated 12-15% of Kenvue's earnings, and track legal defense costs.
- UK Talc-Based Product Group Action LawsuitTrigger: Developments in the UK group action lawsuit over claims that talc-based products cause cancerAction: Evaluate potential liabilities assumed outside the US and Canada as part of the spin-off from Johnson & Johnson.
Research as of 2 Sep 2026